Condition: Anal Squamous Cell Carcinoma · Sponsor: University Health Network, Toronto
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
This description comes directly from the study's public registry record.
Ali Hosni · 416-946-2360 · ali.hosni@uhn.ca
Always discuss trial participation with your own doctor first.
| Allegheny Health Network | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
| Medical College of Wisconsin Cancer Center | Milwaukee, Wisconsin, United States | Not Yet Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Not Yet Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| CHUM - Centre hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06050707